Receptor News and Research

RSS

Genetic insights into reproductive health and longevity

Led by researchers from the University of Oxford's Leverhulme Centre for Demographic Science and the University of Iceland, the review explores how genetic variations can explain differences in reproductive health and longevity.

14 Dec 2024

ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Study unveils key mechanism behind prostate cancer's uncontrolled growth

Prostate cancer hijacks the normal prostate's growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers.

14 Dec 2024

Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer would have better outcomes from adding CDK4/6 inhibitors to endocrine therapy as first-line treatment, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Targeted gene therapy shuts down cancer cells' energy centers

Researchers are shining a light on cancer cells' energy centers – literally – to damage these power sources and trigger widespread cancer cell death.

14 Dec 2024

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Disrupting the circadian rhythm of glioblastoma slows tumor growth, study says

Virtually every cell in the human body has an internal clock. These clocks take their cues from a central clock in the brain. In a normal, biological process called synchrony, the central clock coordinates daily rhythms around the body, so that every cell and tissue recognizes the same external time of day.

13 Dec 2024

A genetic variant modulates interferon signaling and disease risk

For years, scientists have looked to a critical piece of immune system machinery - known as the interferon pathway - for answers. There, when our cells sense an infection, they release a protein known as interferon, which warns other cells to fight the virus.

13 Dec 2024

Key to LDL clearance uncovered: Structural details of apoB100-LDLR binding emerge

Researchers reveal the structural details of apoB100's interaction with LDL receptors, offering insights into LDL dimerization and potential treatments for familial hypercholesterolemia.

12 Dec 2024

New study identifies potential target for treating diabetic cardiomyopathy

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders.

12 Dec 2024

Active monitoring for low-risk DCIS results in similar quality of life as standard treatment

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

COMET trial shows active monitoring is noninferior to standard treatment for low-risk DCIS

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as those who underwent guideline-concordant treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

12 Dec 2024

Tamoxifen lowers breast cancer recurrence in good-risk DCIS patients

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

Gene therapy to prevent stillbirth and premature delivery developed

Researchers investigate the effectiveness of placental nano-based insulin-like 1 growth factor gene therapy to correct fetal growth restriction.

12 Dec 2024

Novel treatment for inflammatory skin conditions could be on the horizon

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of Pittsburgh study published today in Science Translational Medicine.

11 Dec 2024

Study offers a potential pathway for safer, non-addictive pain management

Researchers from the National University of Singapore (NUS), in collaboration with Peking University, China, have made a discovery regarding the TRPV1 (transient receptor potential vanilloid 1) ion channel and its role in pain perception.

11 Dec 2024

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer - as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status - according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Risk-reducing surgeries provide benefits for young BRCA-mutation carriers

Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing salpingo-oophorectomy (RRSO) had lower rates of recurrence, secondary breast and/or ovarian malignancies, and death than those who did not undergo these surgeries, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024